Garland Capital Management Inc Abb Vie Inc. Transaction History

Garland Capital Management Inc

$130 Million
Q3 2024

A detailed history of Garland Capital Management Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Garland Capital Management Inc holds 38,183 shares of ABBV stock, worth $7.68 Million. This represents 5.79% of its overall portfolio holdings.

Number of Shares

38,183

Previous 44,558 14.31%

Holding current value

$7.68 Million

Previous $7.64 Million 1.33%

% of portfolio

5.79%

Previous 5.4%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 30, 2024	SELL	$163.84 - $199.33 $1.04 Million - $1.27 Million	-6,375 Reduced 14.31%	38,183 $7.54 Million
Q2 2024 Jul 30, 2024	SELL	$154.79 - $180.76 $15,479 - $18,076	-100 Reduced 0.22%	44,558 $7.64 Million
Q1 2024 Apr 30, 2024	SELL	$159.82 - $182.1 $75,115 - $85,587	-470 Reduced 1.04%	44,658 $8.13 Million
Q4 2023 Jan 29, 2024	SELL	$137.6 - $154.97 $269,696 - $303,741	-1,960 Reduced 4.16%	45,128 $6.99 Million
Q3 2023 Oct 31, 2023	SELL	$133.59 - $154.65 $10,019 - $11,598	-75 Reduced 0.16%	47,088 $7.02 Million
Q2 2023 Jul 20, 2023	BUY	$132.51 - $164.9 $23,189 - $28,857	175 Added 0.37%	47,163 $6.35 Million
Q1 2023 Apr 25, 2023	SELL	$144.61 - $166.54 $400,569 - $461,315	-2,770 Reduced 5.57%	46,988 $7.49 Million
Q4 2022 Jan 19, 2023	SELL	$138.31 - $165.87 $691 - $829	-5 Reduced 0.01%	49,758 $0
Q3 2022 Oct 20, 2022	BUY	$134.21 - $153.93 $3,355 - $3,848	25 Added 0.05%	49,763 $6.68 Million
Q2 2022 Jul 20, 2022	SELL	$137.62 - $174.96 $179,869 - $228,672	-1,307 Reduced 2.56%	49,738 $7.62 Million
Q1 2022 Apr 27, 2022	SELL	$131.98 - $163.75 $98,984 - $122,812	-750 Reduced 1.45%	51,045 $8.28 Million
Q4 2021 Feb 03, 2022	SELL	$107.43 - $135.93 $370,633 - $468,958	-3,450 Reduced 6.24%	51,795 $7.01 Million
Q3 2021 Oct 27, 2021	SELL	$106.4 - $120.78 $31,920 - $36,234	-300 Reduced 0.54%	55,245 $5.96 Million
Q2 2021 Jul 27, 2021	SELL	$105.21 - $117.21 $10,521 - $11,721	-100 Reduced 0.18%	55,545 $6.26 Million
Q1 2021 Apr 21, 2021	SELL	$102.3 - $112.62 $20,460 - $22,524	-200 Reduced 0.36%	55,645 $6.02 Million
Q4 2020 Feb 09, 2021	BUY	$80.49 - $108.67 $14,085 - $19,017	175 Added 0.31%	55,845 $5.98 Million
Q3 2020 Apr 21, 2021	SELL	$85.91 - $100.83 $6.55 Million - $7.69 Million	-76,270 Reduced 57.81%	55,670 $4.88 Million
Q3 2020 Oct 22, 2020	BUY	$85.91 - $100.83 $6.54 Million - $7.67 Million	76,070 Added 136.16%	131,940 $11.6 Million
Q2 2020 Jul 24, 2020	SELL	$73.37 - $98.18 $78,872 - $105,543	-1,075 Reduced 1.89%	55,870 $5.49 Million
Q1 2020 Apr 13, 2020	SELL	$64.5 - $97.79 $75,787 - $114,903	-1,175 Reduced 2.02%	56,945 $4.34 Million
Q3 2019 Oct 10, 2019	SELL	$62.98 - $75.72 $18,894 - $22,716	-300 Reduced 0.51%	58,120 $4.4 Million
Q2 2019 Jul 24, 2019	SELL	$65.7 - $83.98 $49,603 - $63,404	-755 Reduced 1.28%	58,420 $4.25 Million
Q1 2019 Apr 18, 2019	BUY	$77.14 - $90.79 $80,997 - $95,329	1,050 Added 1.81%	59,175 $4.77 Million
Q4 2018 Jan 24, 2019	BUY	$77.85 - $96.01 $30,127 - $37,155	387 Added 0.67%	58,125 $5.36 Million
Q3 2018 Mar 12, 2019	SELL	$88.91 - $98.84 $78,418 - $87,176	-882 Reduced 1.5%	57,738 $5.46 Million
Q2 2018 Jul 13, 2018	SELL	$89.78 - $106.23 $90,318 - $106,867	-1,006 Reduced 1.69%	58,620 $5.43 Million
Q1 2018 Apr 24, 2018	BUY	$92.01 - $123.21 $39,104 - $52,364	425 Added 0.72%	59,626 $5.64 Million
Q4 2017 Jan 25, 2018	SELL	$89.56 - $98.21 $721,405 - $791,081	-8,055 Reduced 11.98%	59,201 $5.73 Million
Q3 2017 Nov 09, 2017	BUY	$69.85 - $89.22 $4.7 Million - $6 Million	67,256	67,256 $5.98 Million

Others Institutions Holding ABBV

# of Institutions

3,783

Shares Held

1.28B

Call Options Held

13M

Put Options Held

9.82M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $356B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Garland Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Garland Capital Management Inc with notifications on news.

Account

Garland Capital Management Inc Abb Vie Inc. Transaction History